Onkos Surgical® Unveils Innovation Center to Combat Bacterial Contamination

In a strategic move to revolutionize antibacterial technology in orthopaedic surgery, Onkos Surgical has launched a pioneering innovation center right in Bridgewater, New Jersey. Nestled in the prestigious New Jersey Center of Excellence Campus, this facility marks a crucial advancement in the fight against bacterial contamination in operating rooms.

A Cutting-Edge Facility

Spanning 4,600 square feet, the facility is poised to streamline Onkos Surgical’s innovation process for NanoCept® Antibacterial Technology. As the first commercially available orthopaedic antibacterial coating in the U.S., NanoCept® offers transformative potential to minimize risks associated with bacterial contamination during complex procedures.

Commitment to Reshaping Orthopaedic Solutions

The decision to establish a new manufacturing hub is a testament to Onkos Surgical’s commitment to delivering innovative solutions for orthopaedic implants. Patrick Treacy, Founder and CEO of Onkos Surgical, emphasizes the significance of this expansion: “This investment accelerates the delivery of groundbreaking technology to surgeons, enhancing our capacity to assist patients grappling with complex orthopaedic challenges.”

Surgeons’ Perspectives and Empowerment

Dr. Steven Gitelis, Director of the Orthopaedic Oncology Program at Rush University, acknowledges the pivotal role of NanoCept® in empowering surgeons: “This unique technology elevates our capacity to address the formidable challenge of bacteria in operating theaters.”

A Milestone for New Jersey

Congressman Tom Kean, Jr. praises the enduring impact of Onkos Surgical’s initiatives, stating, “The opening of the NanoCept Innovation Center epitomizes the innovation that sets New Jersey’s 7th Congressional District apart.” This cutting-edge facility not only promises progress in medicine but also fortifies Onkos Surgical’s ties with the local community. As stated in Ortho Spine News, community engagement remains a core value for the company.

The Bigger Picture

As Onkos Surgical embarks on this remarkable journey, they aim to integrate NanoCept® Antibacterial Technology into more implants, ultimately paving the way for enhanced patient care. With a stronghold in over 350 leading medical institutions, the company’s commitment to precision and innovation remains unwavering.

In a world where surgical excellence is paramount, Onkos Surgical continues to lead with groundbreaking advancements, reshaping the future of orthopaedic care one innovation at a time.